This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
According to preliminary results from a phase I trial, VS-6766, also known as CH5126766, a first-in-class dual RAF–MEK inhibitor, is safe and has shown some efficacy in solid tumors and multiple myeloma harboring various RAS–RAF mutations.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Dual RAF–MEK Inhibitor Assessed
Jump to section
Advertisement